Japanese regulators outline acceptable collaborations among generic drug makers
MLex Summary: Japan's healthcare and competition regulators today jointly published examples of acceptable collaborations among generic drug makers under the Antimonopoly Act, addressing the recent public concern over shortages of certain...To view the full article, register now.
Already a subscriber? Click here to view full article